Initial Conservative Strategy

Preclinical

Initial Conservative Strategy is one of 47 therapeutic programs targeting Coronary Artery Disease. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Coronary Artery DiseaseNot yet recruiting

Coronary Artery DiseasePreclinical

Not yet recruiting

Competition

Competitive Landscape

117 competitors in Coronary Artery Disease

#DrugCompanyPhaseTrials

Bayer Aspirin

Bayer

Approved

15 2

Brilinta

AstraZeneca

Approved

13 3

Crestor

AstraZeneca

Approved

6 4

Niacor

AbbVie

Approved

2 5

Ozempic

Novo Nordisk

Approved

2 6

Effient

CCosette Pharmaceuticals, Inc.

Approved

8 7

Glucophage

EMD Serono

Approved

5 8

Aggrastat

MMedicure

Approved

1 9

Ranexa

MMenarini International Operations Luxembourg SA

Approved

1 10

Cardizem

BBausch Health Americas, Inc.

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2031

PreclinicalNot yet recruiting

Coronary Artery Disease

NCT07569692

Clinical

Trials by Indication[1]

Coronary Artery Disease1 trial

A Comparison of Initial Invasive Strategy and Initial Conservative Strategy for the Treatment of Vulnerable Atherosclerotic Coronary Plaques Identified by Coronary CT Angiography

Not yet recruiting·DDuk-Woo Park, MD·Preclinical·NCT07569692·2,500 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Initial Conservative Strategy. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Initial Conservative Strategy. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Duk-Woo Park, MD company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: DDuk-Woo Park, MD

Initial Conservative Strategy

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2031

Trials by Indication[1]

Coronary Artery Disease1 trial

References

Drug Info

Quick Facts

Related News